The DOI matches its Crossref record; 226 of the 226 references it cites were found in a registry or an index.
Immuno-Oncology: Emerging Targets and Combination Therapies
Open accessAbstract
Host immunity recognizes and eliminates most early tumor cells, yet immunological checkpoints, exemplified by CTLA-4, PD-1 and PD-L1, pose a significant obstacle to effective antitumor immune responses. T-lymphocyte co-inhibitory pathways influence intensity, inflammation and duration of antitumor immunity. However, tumors and their immunosuppressive microenvironments exploit them to evade immune destruction. Recent PD-1 checkpoint inhibitors yielded unprecedented efficacies and durable responses across advanced-stage melanoma, showcasing potential to replace conventional radiotherapy regimens. Neverthless, many clinical problems remain in terms of efficacy, patient-to-patient variability and undesirable outcomes and side effects. In this review, we evaluate recent advances in the immuno-oncology field and discuss ways forward. First, we give an overview of current immunotherapy modalities, involving mainy single agents, including inhibitor monoclonal antibodies (mAbs) targeting T-cell checkpoints of PD-1 and CTLA-4. However, neoantigen recognition alone cannot eliminate tumors effectively in vivo given their inherent complex micro-environment, heterogeneous nature and stemness. Then, based mainly upon CTLA-4 and PD-1 checkpoint inhibitors as a ‘backbone’, we cover a range of emerging (‘second-generation’) therapies incorporating other immunotherapies or non-immune based strategies in synergistic combination. These include targeted therapies such as tyrosine kinase inhibitors, co-stimulatory mAbs, bifunctional agents, epigenetic modulators (such as inhibitors of histone deacetylases or DNA methyltransferase), vaccines, adoptive-T-cell therapy, nanoparticles, oncolytic viruses, and even synthetic ‘gene circuits’. A number of novel immunotherapy co-targets in pre-clinical development are also introduced. The latter include metabolic components, exosomes and ion channels. We discuss in some detail of the personalization of immunotherapy essential for ultimate maximization of clinical outcomes. Finally, we outline possible future technical and conceptual developments including realistic in vitro and in vivo models and inputs from physics, engineering and articial intelligence. We conclude that the breadth and quality of immunotherapeutic approaches and the types of cancers that can be treated will increase significantly in the foreseeable future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–226 of 226
Mutation Drivers of Immunological Responses to Cancer
Porta‐Pardo, E., & Godzik, A. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0233 · Cited by 45
Bifacial effects of engineering tumour cell-derived exosomes on human natural killer cells
Li, Q., Huang, Q., Huyan, T., Wang, Y., Huang, Q., & Shi, J. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.005 · Cited by 44
Review Immunotargeting of cancer stem cells
Kwiatkowska-Borowczyk, E. P., Gąbka-Buszek, A., Jankowski, J., & Mackiewicz, A. A. (2015) · Współczesna Onkologia · doi:10.5114/wo.2014.47129 · Cited by 40
Fairhurst, C. M., Watt, I., Martin, F., Bland, M., & Brackenbury, W. J. (2015) · Scientific Reports · doi:10.1038/srep16758 · Cited by 38
Webb, S. (2016) · Nature Biotechnology · doi:10.1038/nbt.3717 · Cited by 38
Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land
Guo, Z. S., & Bartlett, D. L. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.31 · Cited by 31
Atkins, M. B., Plimack, E. R., Puzanov, I. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw373.01 · Cited by 31
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
Thomas, X., & Jeune, C. L. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s83848 · Cited by 29
Heuser-Loy, C., Becker-Gotot, J., Piotrowski, E. C., Philipp, M., Courrèges, C. J. F., Otte, M. S., Guo, L., Schmid-Burgk, J. L., Hornung, V., Heine, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.082 · Cited by 28
Bajor, D. L., Mick, R., Riese, M. J., Richman, L. P., Xu, X., Torigian, D. A., Stelekati, E., Sweeney, M., Sullivan, B. J., Schuchter, L. M., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ct137 · Cited by 27
McKee, S. J., Doff, B. L., Soon, M. S. F., & Mattarollo, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0249 · Cited by 25
Propelling Immunotherapy Combinations Into the Clinic.
Tchekmedyian, N., Gray, J. E., Creelan, B., et al. (2015) · PubMed · Cited by 20
Gong, C., Ni, Z., Yao, C., Zhu, X., Ni, L., Wang, L., & Zhu, S. (2015) · Biological Procedures Online · doi:10.1186/s12575-015-0026-6 · Cited by 18
Perspective on the dynamics of cancer
Derbal, Y. (2017) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-017-0066-5 · Cited by 18
Predictors of clinical response to immunotherapy with or without radiotherapy
Hiniker, S. M., Maecker, H. T., & Knox, S. J. (2015) · Journal of Radiation Oncology · doi:10.1007/s13566-015-0219-2 · Cited by 17
Kvistborg, P., Clynes, R., Song, W., & Yuan, J. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0126-0 · Cited by 17
Is the exosome a potential target for cancer immunotherapy?
Yoshimura, A., Sawada, K., & Kimura, T. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.01.47 · Cited by 16
Conditioning neoadjuvant therapies for improved immunotherapy of cancer
Benson, Z., Manjili, S. H., Habibi, M., Guruli, G., Toor, A. A., Payne, K. K., & Manjili, M. H. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.007 · Cited by 14
Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy
Garber, K. (2017) · Nature Biotechnology · doi:10.1038/nbt0417-297a · Cited by 13
The role of pembrolizumab in the treatment of advanced non-small cell lung cancer
Santabarbara, G., Maione, P., Rossi, A., Palazzolo, G., & Gridelli, C. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.64 · Cited by 12
Fiering, S. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.89 · Cited by 12
Devaud, C., Westwood, J. A., Teng, M. W. L., John, L. B., Yong, C. S. M., Duong, C. P. M., Smyth, M. J., Darcy, P. K., & Kershaw, M. H. (2014) · OncoImmunology · doi:10.4161/21624011.2014.963395 · Cited by 9
Refining Immunotherapy Approvals
Bates, S. E. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2025 · Cited by 9
Isakov, N. (2016) · Journal of Autoimmune Disorders · doi:10.21767/2471-8513.100017 · Cited by 8
A voltage-gated sodium channel mediates positive selection of T cells
MALISSEN, B. (2012) · Nature Immunology · doi:10.1038/ni.2400 · Cited by 4
Frampton, G. M., Fabrizio, D. A., Chalmers, Z. R., Sun, J., Miller, V. A., & Stephens, P. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw363.01 · Cited by 4
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
The importance of exosomal PDL1 in tumour immune evasion
Daassi, D., Mahoney, K. M., & Freeman, G. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0264-y · Cited by 598
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
The IL-17 family in diseases: from bench to bedside
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01620-3 · Cited by 452
Metadata
- Authors
- Marshall, H. T., & Djamgoz, M. B. A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2018-08-23
- Volume
- 8
- Pages
- 315-315
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2888555926
- Cited by
- 301
- References
- 226
- FWCI
- 13.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.